Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : starts share buyback, highlights product pipeline

11/24/2020 | 01:36am EST
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison

ZURICH (Reuters) - Novartis is initiating a previously announced share buyback worth up to $2.5 billion, it said on Tuesday as it highlighted its research and development pipeline in an investor presentation.

The Swiss drugmaker also increased its target for a technical operations productivity programme starting in 2021 to $2 billion from $1.5 billion and said it was committed to driving constant margin expansion.

Novartis said its product pipeline was set to fuel growth in the mid-to long-term.

"The total value of estimated sales of products launched from 2020 to 2026 puts Novartis as number two for pipeline replacement power in the global pharmaceutical industry," it said.

The share buyback starts immediately and will last into the first half of 2021, it said.

(Reporting by Michael Shields; editing by Thomas Seythal and Brenna Hughes Neghaiwi)


© Reuters 2020
All news about NOVARTIS AG
05:30aNOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
03:56aNovartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
MT
03:00aNovartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
MT
02:56aGSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
RE
01:40aNOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
01:26aNOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/17NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
More news
Financials (USD)
Sales 2020 49 208 M - -
Net income 2020 8 211 M - -
Net Debt 2020 19 211 M - -
P/E ratio 2020 26,0x
Yield 2020 3,31%
Capitalization 217 B 217 B -
EV / Sales 2020 4,80x
EV / Sales 2021 4,40x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,18 $
Last Close Price 95,42 $
Spread / Highest target 47,6%
Spread / Average Target 14,4%
Spread / Lowest Target -13,9%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.65%217 178
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120